Henry Schein stock holds around $90 as investors weigh FY 2026 EPS guidance
Published on 08/28/2026 at 11:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Henry Schein Inc. (ISIN US42548G1040) stock is trading close to the $90 mark in late August 2026, with recent market data showing the shares at $90.28 at the close on August 27, 2026, in Nasdaq trading. This places the stock just below its one-year high near $90.38 and provides a visible reference point for investors tracking the company’s valuation against its earnings outlook.
Share price, late-August levels and valuation context
A recent Nasdaq quote snapshot reported Henry Schein shares at $90.28 at the regular-session close on August 27, 2026, with the same level in after-hours trading later that day. The price level indicates only a marginal change on the day, with a decline of 0.10 points or 0.11 percent from the previous close, underscoring that the stock is consolidating rather than experiencing a sharp swing at the end of August. At the same time, other market data placed the opening quote on August 27, 2026, at $90.38, showing that the intraday range during that session sat tightly within a band of less than $0.20.
The narrow movement around the $90 handle matters because it keeps Henry Schein stock close to the late-August highs implied by its recent trading history. When compared with the consensus price target of $92.93 compiled from current analyst models, the August 27, 2026 close of $90.28 signals an implied upside of $2.65 per share or roughly 2.9 percent. This modest gap highlights a market view that already prices in much of the anticipated operational progress while still acknowledging limited room for gains if the company delivers on its guidance.
In addition to the headline price, the recent price performance links back to a longer-run appreciation narrative. Prior coverage has referenced a prior closing level of $76.85 used in a three-year performance example, against which the current late-August price near $90 implies a gain of more than $13 per share over that multi-year period. That rise translates into double-digit percentage appreciation and signals that investors have been rewarded over the longer term for backing Henry Schein’s strategy in dental and medical distribution.
Guidance for FY 2026 EPS and analyst consensus view
Beyond the day-to-day price context, the latest available fundamentals show that Henry Schein has set guidance for fiscal 2026 earnings per share in a band that reflects measured growth. Recent coverage of management’s outlook indicates that the company is targeting FY 2026 EPS in a range from $5.29 to $5.39. Within that band, the midpoint of $5.34 provides a useful reference for valuation work, because it sits very close to the $5.35 level implied by current consensus forecasts.
The alignment between Henry Schein’s internal guidance and analyst expectations is reinforced by commentary noting that analysts as a group currently anticipate FY 2026 EPS of $5.36. In practice, this figure lands within the company’s guided range and slightly above the midpoint, suggesting that external models lean toward the upper half of the guidance corridor. For investors, the number stands out because it helps translate the late-August share price into a forward price-to-earnings multiple: using the August 27, 2026 close of $90.28 and the $5.36 consensus, the forward P/E ratio is near 16.8, a level that can be compared with peers in healthcare distribution and broader market benchmarks.
Analyst sentiment toward Henry Schein mirrors this generally constructive earnings picture. The latest compiled data indicate that the stock carries a consensus rating described as moderate buy, based on a mix of nine buy recommendations, five hold ratings and one sell call. When tied to the average price target of $92.93, which spans an underlying range from low estimates near $82 and high targets up to $110, this rating configuration underscores that most covering analysts expect the shares to deliver incremental gains rather than significant downside from current levels, although the presence of a single sell rating does introduce a note of caution.
One useful quantitative comparison for investors is the relationship between the August 27, 2026 price and the consensus target band. With the stock trading at $90.28, it sits just $2.65 below the $92.93 average target and $8.28 above the most cautious $82 forecast, while being $19.72 below the most optimistic $110 target. This spread illustrates the range of possible outcomes that analysts see for Henry Schein over the medium term and demonstrates that the current price is closer to the center of the distribution than to its extremes.
Institutional interest and longer-term positioning
Recent filings have highlighted that institutional investors continue to adjust their exposure to Henry Schein, offering an additional lens on how the market perceives the stock. A disclosure dated August 28, 2026 reported that one large asset manager’s position in Henry Schein involved 505,999 shares, pointing to sustained institutional-scale interest in the company’s equity. While the filing itself focuses on share counts and portfolio mechanics rather than strategic commentary, it adds weight to the impression that major investors see Henry Schein as a core holding within healthcare distribution.
Another portfolio update noted that a different investment manager initiated a new holding in Henry Schein toward late August 2026. The same analysis highlighted the connection between the new investment and the company’s FY 2026 guidance and analyst consensus, stating that the management EPS range and the $5.36 consensus forecast underpin the valuation rationale. The report also emphasized that near-term estimate reductions in certain models inject some caution, even as the FY 2026 projection remains close to the guidance midpoint, indicating that expectations have become slightly more conservative while still assuming earnings growth.
Viewed together, these institutional disclosures underscore that Henry Schein remains on the radar of large professional investors, who balance the appeal of steady EPS progress and a supportive moderate buy rating against the reality that the shares already trade at a forward multiple that is neither deep-value nor high-growth. For retail investors, this mix can translate into a case where the stock serves as a diversified healthcare holding rather than a speculative momentum vehicle.
Operational backdrop behind the numbers
Although the freshest available coverage in late August 2026 centers on guidance, consensus and valuation, Henry Schein’s operating environment provides important context for those figures. The company is a global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. That positioning gives Henry Schein exposure to demand for consumables, equipment and digital solutions across a broad customer base, which can stabilize revenue flows even when individual segments face cyclical pressures.
Historically, Henry Schein’s earnings profile has been shaped by a combination of volume trends in dental and medical practices, shifts toward higher-value products and services, and the company’s ability to manage margins through efficiency initiatives. Previous annual reports have highlighted that revenue growth in dental supplies and equipment, as well as expansion in technology and value-added services, can support profit improvements even when broader economic conditions are mixed. While those older figures fall outside the strict freshness window for current metrics, they illustrate the type of drivers that likely underpin the FY 2026 EPS guidance band.
In the current period, external commentary points toward management focusing on disciplined capital allocation and targeted acquisitions within its core healthcare channels. This strategy is consistent with Henry Schein’s long-standing approach of enhancing its portfolio through bolt-on deals and partnerships, while remaining attentive to balance-sheet strength. For investors interpreting the FY 2026 guidance, the key is whether these operational initiatives can sustain mid-teens forward P/E valuation levels in the face of industry competition and any reimbursement or cost pressures.
Representative product: Henry Schein dental supply offering
A representative example of Henry Schein’s business can be found in its extensive dental supply offering, which includes products such as restorative materials, sterilization equipment and practice management solutions made available through its online catalog. By providing a broad range of items that dental practices need on a routine basis, Henry Schein positions itself as a one-stop partner for clinics aiming to manage inventory efficiently and maintain consistent standards of care.
Within that portfolio, Henry Schein’s own-brand consumables illustrate how the company can capture margin through private-label products while still meeting practitioner requirements for quality and reliability. These items span categories from basic disposables to specialized restorative materials and often benefit from the company’s distribution network and customer-service capabilities. For investors, the presence of such proprietary offerings matters because they can support margins at scale and contribute to the earnings base that feeds into the FY 2026 EPS guidance range.
Stock takeaway at current price levels
At the late-August 2026 close of $90.28 on August 27, Henry Schein stock trades within a tight band below its one-year high near $90.38 and modestly under the $92.93 consensus price target, reflecting a valuation that already incorporates much of the expected FY 2026 EPS performance while leaving limited but tangible upside potential if management meets or slightly exceeds the guided $5.29 to $5.39 earnings per share range.
Fact box
Company: Henry Schein Inc.
ISIN: US42548G1040
Ticker: HSIC
Exchange: Nasdaq
Price (as of August 27, 2026, 4:00 p.m. ET): $90.28 USD
Sector / Industry: Health Care / Health Care Distributors
Index membership: S&P 500
Read more
Investor Relations
